Vera Therapeutics Shares Rise After Q3 Results

MT Newswires Live

2024/11/08

Vera Therapeutics (VERA) share were up more than 2% in recent Thursday trading after the clinical-stage biotechnology company reported its Q3 results.

Earlier, Vera reported a Q3 net loss of $0.85 per diluted share, compared with a loss of $0.45 a year ago. Analysts polled by Capital IQ expected a loss of $0.66.

As expected, no revenue for the quarter ended Sept. 30 was reported.

The company said its balance sheet will be sufficient to fund operations through the potential approval and US commercial launch of atacicept.

Price: 49.02, Change: +1.08, Percent Change: +2.25

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2481137415"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481137415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481137415?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 02:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481137415","market":"sh","top_or_hot":-1,"title":"Vera Therapeutics Shares Rise After Q3 Results","media":"MT Newswires Live","content":"<html><body><p> Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VERA) share were up more than 2% in recent Thursday trading after the clinical-stage biotechnology company reported its Q3 results.</p><p>Earlier, Vera reported a Q3 net loss of $0.85 per diluted share, compared with a loss of $0.45 a year ago. Analysts polled by Capital IQ expected a loss of $0.66.</p><p>As expected, no revenue for the quarter ended Sept. 30 was reported.</p><p>The company said its balance sheet will be sufficient to fund operations through the potential approval and US commercial launch of atacicept.</p><p>Price: 49.02, Change: +1.08, Percent Change: +2.25</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics Shares Rise After Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics Shares Rise After Q3 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-11-08 02:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VERA) share were up more than 2% in recent Thursday trading after the clinical-stage biotechnology company reported its Q3 results.</p><p>Earlier, Vera reported a Q3 net loss of $0.85 per diluted share, compared with a loss of $0.45 a year ago. Analysts polled by Capital IQ expected a loss of $0.66.</p><p>As expected, no revenue for the quarter ended Sept. 30 was reported.</p><p>The company said its balance sheet will be sufficient to fund operations through the potential approval and US commercial launch of atacicept.</p><p>Price: 49.02, Change: +1.08, Percent Change: +2.25</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481137415","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481137415","pubTimestamp":1731004721,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vera Therapeutics  share were up more than 2% in recent Thursday trading after the clinical-stage biotechnology company reported its Q3 results.Earlier, Vera reported a Q3 net loss of $0.85 per diluted share, compared with a loss of $0.45 a year ago. Analysts polled by Capital IQ expected a loss of $0.66.As expected, no revenue for the quarter ended Sept. 30 was reported.The company said its balance sheet will be sufficient to fund operations through the potential approval and US commercial launch of atacicept.Price: 49.02, Change: +1.08, Percent Change: +2.25","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","LENZ":"Therapeutics","VERA":"Vera Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Vera Therapeutics股价在第三季度业绩公布后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":1,"LENZ":1},"content_text":"Vera Therapeutics (VERA) share were up more than 2% in recent Thursday trading after the clinical-stage biotechnology company reported its Q3 results.Earlier, Vera reported a Q3 net loss of $0.85 per diluted share, compared with a loss of $0.45 a year ago. Analysts polled by Capital IQ expected a loss of $0.66.As expected, no revenue for the quarter ended Sept. 30 was reported.The company said its balance sheet will be sufficient to fund operations through the potential approval and US commercial launch of atacicept.Price: 49.02, Change: +1.08, Percent Change: +2.25","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}